Symptomatic diverticular disease (SYMP-DD) and irritable bowel syndrome (IBS) share many features. Both are characterised by recurrent episodes of abdominal pain which may be slightly more frequent in IBS than SYMP-DD. They may also both exhibit an erratic bowel habit with diarrhoea, constipation and alternating types. It is important to assess anxiety, depression and somatisation since this can be increased in both types of patients and may be associated with visceral hypersensitivity. There are also significant differences between IBS and SYMP-DD. In particular, SYMP-DD patients are older, lack the female predominance seen in IBS and may often have fever with prolonged episodes of pain. For them, abnormalities of the gut are probably more important than cerebral factors, while for IBS the reverse is true. Treatments should be directed at the predominant abnormality which will vary in every patient.

1.
Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC: Functional bowel disorders. Gastroenterology 2006;130:1480–1491.
2.
Simpson J, Neal KR, Scholefield JH, Spiller RC: Patterns of pain in diverticular disease and the influence of acute diverticulitis. Eur J Gastroenterol Hepatol 2003;15:1005–1010.
3.
Jones R, Latinovic R, Charlton J, Gulliford M: Physical and psychological co-morbidity in irritable bowel syndrome: a matched cohort study using the General Practice Research Database. Aliment Pharmacol Ther 2006;24:879–886.
4.
Jung HK, Choung RS, Locke GR, III, Schleck CD, Zinsmeister AR, Talley NJ: Diarrhea-predominant irritable bowel syndrome is associated with diverticular disease: a population-based study. Am J Gastroenterol 2010;105:652–661.
5.
Stevens JA, Wan CK, Blanchard EB: The short-term natural history of irritable bowel syndrome: a time-series analysis. Behav Res Ther 1997;35:319–326.
6.
Spiller RC, Humes DJ, Campbell E, Hastings M, Neal KR, Dukes GE, Whorwell PJ: The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease. Aliment Pharmacol Ther 2010;32:811–820.
7.
Weinland SR, Morris CB, Hu Y, Leserman J, Bangdiwala SI, Drossman DA: Characterization of episodes of irritable bowel syndrome using ecological momentary assessment. Am J Gastroenterol 2011;106:1813–1820.
8.
Stone AA, Schwartz JE, Broderick JE, Deaton A: A snapshot of the age distribution of psychological well-being in the United States. Proc Natl Acad Sci USA 2010;107:9985–9990.
9.
Nicholl BI, Halder SL, Macfarlane GJ, Thompson DG, O’brien S, Musleh M, McBeth J: Psychosocial risk markers for new onset irritable bowel syndrome – results of a large prospective population-based study. Pain 2008;137:147–155.
10.
Aldoori WH, Giovannucci EL, Rimm EB, Wing AL, Trichopoulos DV, Willett WC: A prospective study of diet and the risk of symptomatic diverticular disease in men. Am J Clin Nutr 1994;60:757–764.
11.
Aldoori WH, Giovannucci EL, Rimm EB, Ascherio A, Stampfer MJ, Colditz GA, Wing AL, Trichopoulos DV, Willett WC: Prospective study of physical activity and the risk of symptomatic diverticular disease in men. Gut 1995;36:276–282.
12.
Strate LL, Liu YL, Aldoori WH, Syngal S, Giovannucci EL: Obesity increases the risks of diverticulitis and diverticular bleeding. Gastroenterology 2009;136:115–122.
13.
Schaffler A, Scholmerich J: The role of adiponectin in inflammatory gastrointestinal diseases. Gut 2009;58:317–322.
14.
Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–370.
15.
Humes DJ, Simpson J, Neal KR, Scholefield JH, Spiller RC: Psychological and colonic factors in painful diverticulosis. Br J Surg 2008;95:195–198.
16.
Kroenke K, Spitzer RL, Williams JB: The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002;64:258–266.
17.
Kroenke K: Physical symptom disorder: a simpler diagnostic category for somatization-spectrum conditions. J Psychosom Res 2006;60:335–339.
18.
Simpson J, Sundler F, Humes DJ, Jenkins D, Wakelin D, Scholefield JH, Spiller RC: Prolonged elevation of galanin and tachykinin expression in mucosal and myenteric enteric nerves in trinitrobenzene sulphonic acid colitis. Neurogastroenterol Motil 2008;20:392–406.
19.
Simpson J, Sundler F, Humes DJ, Jenkins D, Scholefield JH, Spiller RC: Post-inflammatory damage to the enteric nervous system in diverticular disease and its relationship to symptoms. Neurogastroenterol Motil 2009;21:847–858.
20.
Francis CY, Morris J, Whorwell PJ: The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11:395–402.
21.
Miller AR, North CS, Clouse RE, Wetzel RD, Spitznagel EL, Alpers DH: The association of irritable bowel syndrome and somatization disorder. Ann Clin Psychiatry 2001;13:25–30.
22.
Clemens CH, Samsom M, Roelofs J, Berge Henegouwen GP, Smout AJ: Colorectal visceral perception in diverticular disease. Gut 2004;53:717–722.
23.
Cervero F, Laird JM, Garcia-Nicas E: Secondary hyperalgesia and presynaptic inhibition: an update. Eur J Pain 2003;7:345–351.
24.
Dorn SD, Palsson OS, Thiwan SI, Kanazawa M, Clark WC, van Tilburg MA, Drossman DA, Scarlett Y, Levy RL, Ringel Y, Crowell MD, Olden KW, Whitehead WE: Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. Gut 2007;56:1202–1209.
25.
Zhuo M, Gebhart GF: Facilitation and attenuation of a visceral nociceptive reflex from the rostroventral medulla in the rat. Gastroenterology 2002;122:1007–1019.
26.
Wilder-Smith CH, Schindler D, Lovblad K, Redmond SM, Nirkko A: Brain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controls. Gut 2004;53:1595–1601.
27.
Bouhassira D, Sabate JM, Coffin B, Le Bars D, Willer JC, Jian R: Effects of rectal distensions on nociceptive flexion reflexes in humans. Am J Physiol 1998;275:G410–G417.
28.
Coffin B, Bouhassira D, Sabate JM, Barbe L, Jian R: Alteration of the spinal modulation of nociceptive processing in patients with irritable bowel syndrome. Gut 2004;53:1465–1470.
29.
Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM: The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010;59:325–332.
30.
Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP: Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22–32.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.